查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年泪道支架管的全球市场
市场调查报告书
商品编码
1140677

2022-2029 年泪道支架管的全球市场

Global Lacrimal Duct Stent Tube Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

在预测期内，先进和高度成功的疗法的引入将推动市场增长。

采用精确和升级的泪管设备，例如结合灵活性和强度的新型泪管插管，通过促进进入泪管来减少创伤，是市场增长的关键驱动力。泪道支架和泪囊切除术 (DCR) 是微创手术，在医院范围内的采用率显着增加。此外，验光师、全科医生和进行泪道扩张和灌注的医院对泪道支架管的需求不断增长，预计将在未来几年刺激产品收入。门诊手术中心 (ASC) 和眼科诊所等门诊诊所也使用泪管支架管，因为泪管治疗程序简单且成功率高。此外，使用具有成本效益的泪道支架管所获得的有效结果正在进一步推动该行业的发展。

此外，在审查期间，患有泪管狭窄的患者数量增加正在推动对该产品的需求。鼻泪管阻塞（NLDO）或泪道狭窄是最常见的泪道系统疾病。根据 2020 年发表的论文 "Nasolacrimal Duct Obstruction" ，大约 6.0% 到 20.0% 的新生儿会出现一些症状。NLDO 的自发恢復率很高，大约 70% 的受影响儿童在 3 个月内恢復，超过 90% 在 1 岁内恢復。在另一个例子中，20% 的健康新生儿在出生后第一年泪液引流失败的风险很高。近年来，泪道插管已成为一种非常常见的先天性NLDO手术方法。这种手术对保守的药物治疗或不成功的探查没有反应。还有一些与泪管阻塞相关的健康状况，例如泪囊炎，这是一种鼻泪管炎症，通常在鼻泪管阻塞后发生。由于此类健康状况的高发率，预计在预测期内对该产品的需求将非常高。

与泪道支架管相关的并发症预计将阻碍市场增长。

与泪道支架管相关的各种并发症可能会限制产品需求。硅胶支架的一个常见困难是管移位或横向迁移，这很难纠正。此外，不发达国家验光师和眼科手术医生的短缺进一步阻碍了市场增长。

地理渗透。

北美是预测期内的主要地区。

由于其强大的医疗行业和高昂的医疗保健支出，预计北美地区将在回顾期间创下最高的市场份额。先进和现代化的医疗和眼科设施的存在以及泪腺疾病的显着增加增加了对泪道支架管的需求。在美国和加拿大，人均医疗保健支出的增加和政府对综合医疗保健系统的承诺的增加正在推动区域市场的增长。此外，视网膜疾病的日益流行为市场参与者提供了充足的机会。由于完善的手术设备监管框架以及公众对泪道阻塞及相关疾病手术的意识不断提高，美国在该地区占据主导地位。行业公司与医院、眼科诊所建立了直接的渠道联动，有效服务患者。此外，我们正在战略性地收购知名诊所和医院，以扩大我们在北美的业务。

竞争格局。

由于区域和全球公司的存在，泪道支架管市场竞争适度。全球市场参与者包括 FCI Ophthalmics、Kaneka Medical America LLC、Gunther Weiss Scientific Glassblowing Co.、Aurolab、Beaver-Visitec International, Inc.领先公司正在实施各种增长战略，如收购、产品创新和扩张，为全球泪道支架管市场的增长做出贡献。2021 年 2 月，FCI Ophthalmics 宣布推出用于单室鼻泪管插管的 LacriJet。LacriJet 在美国推出。根据 FCI Ophthalmics 的说法，这是第一个预装到一次性注射器中的自固位单隔室鼻泪管插管。该产品由一个一次性注射器手机组成，金属探头内有硅胶管。专为减少插管和拔除期间的处理时间而设计。适应症包括鼻出血、先天性鼻泪管阻塞 (CNLDO) 和鼻泪管撕裂。2020年6月，Kaneka Corporation完成了与Rohto Pharmaceutical Co., Ltd.的合作。这种伙伴关係扩大了泪管业务。两家公司合作扩大销售。

COVID-19 的影响将对全球泪道支架管市场产生负面影响。

鼻组织已显示 SARS-CoV-2 病毒脱落，对鼻腔的任何干预都可能成为气溶胶的来源。这增加了泪液外科医生和验光师从气溶胶和飞沫中接触病毒的风险。这种风险因在手术和检测期间与患者面对面接触而加剧，手术过程中可能出现咳嗽和打喷嚏，使医护人员的生命处于危险之中。非紧急泪道手术和择期泪道手术的终止影响泪道支架市场。

全球泪道支架管市场报告提供了大约 50 个市场数据表、40 个数字和 170 页的结构。

目录

第一章 调查方法和范围

  • 调查方法
  • 市场范围

第二章主要趋势和发展

第三章执行摘要

  • 按产品划分的市场细分
  • 最终用户的市场细分
  • 区域市场细分

第四章市场动态

  • 市场影响因素
    • 促进者
    • 抑製剂
    • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 价值链分析
  • 专利分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 中的价格动态
  • 供需谱
  • 大流行期间与市场相关的政府努力
  • 製造商的战略举措

第 7 章按产品分类

  • 单室泪道支架管
  • 双囊泪道支架管

第 8 章最终用户

  • 医院
  • 眼科诊所
  • 门诊手术中心

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第 10 章 竞争格局

  • 竞争情景
  • 竞争对手战略分析
  • 市场/份额分析
  • 併购分析

第十一章公司简介

  • FCI Ophthalmics
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Kaneka Pharma America LLC
  • Gunther Weiss Scientific Glass
  • Bess Medizintechnik Gmbh
  • Aurolab
  • Agfa Healthcare
  • Beaver-Visitec International, Inc
  • Carefu（shandong）International Trade Co.,ltd
  • Hangzhou Formed Medical Device Co., Ltd.

第 12 章 数据管理

简介目录
Product Code: DMHCIT2966

Market Overview

Lacrimal Duct Stent Tube Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.2% during the forecast period (2022-2029).

Lacrimal devices are a protective ophthalmic device that helps keep the eye moist and free of dust particles. These devices are generally considered the eye's lacrimal ducts and nasal punctum. These devices play a vital role in repairing and treating lacrimal drainage systems. Lacrimal stents and intubation sets are solely used to treat epiphora both in adults and infants, obstruction, stenosis, and treat conditions necessitating dacryocystorhinostomy. Lacrimal duct stent tubes are small diameter tubes placed within the nasolacrimal system to maintain patency. Typically, the tubes are silicone or similar semi-rigid yet flexible material with an open central lumen. Nasolacrimal tubes are used primarily in lacerations or obstructing one or more parts of the tear drainage system. The global lacrimal duct stent tube market growth is augmented by increasing demand for ophthalmology treatments with better success rates, minimal invasions, and a rise in patients for nasolacrimal duct obstruction.

Market Dynamics: The introduction of advanced and high success rate treatments propel the market growth during the forecast period.

Adopting precise and upgraded lacrimal devices such as the new lacrimal cannula, which combines flexibility and strength to reduce trauma by allowing easy access to the canaliculus, is a key factor proliferating the market growth. As lacrimal duct stent tubes and dacryocystorhinostomy (DCR) surgery are minimally invasive, their adoption has significantly increased across hospitals. Moreover, the growing demand for lacrimal duct stent tubes from an optometrist or general physicians and hospitals performing lacrimal dilation and irrigation is likely to spur product revenue in the following years. Also, outpatient clinics such as ambulatory surgical centers (ASC) and ophthalmic clinics adopt lacrimal duct stent tubes due to the ease and high success rates in lacrimal treatment procedures. Additionally, effective results obtained by using cost-effective lacrimal duct stent tubes further bolster industry growth.

Moreover, the Growing number of patients suffering from dacryostenosis drives the product demand during the review period. Nasolacrimal duct obstruction (NLDO) or dacryostenosis is the most common lacrimal system disorder. According to the article 'Nasolacrimal Duct Obstruction' published in 2020, around 6.0% to 20.0% of newborn patients present with some symptoms. There is a high rate of spontaneous resolution of NLDO, with about 70% of affected children being free of the symptoms within 3 months and more than 90% recovering within a year old. In some cases, 20% of healthy newborn babies were at high risk of defective lacrimal drainage during the first year of life. Lacrimal intubation has been adopted as a very prevalent surgery for congenital NLDO in the past few years. This surgery does not respond to conservative medical treatments or failed probing. Moreover, there are other related health conditions to lacrimal duct obstruction, such as dacryocystitis, an inflammation caused in the nasolacrimal sac and is generally followed by nasolacrimal duct blockage. Due to the high incidence of such health conditions, there is significant demand for the product over the forecast timeline.

Complications related to lacrimal duct stent tubes are expected to hamper the market growth.

Various complications associated with lacrimal duct stent tubes are likely to restrain the product demand. A common difficulty with silicone stents is the displacement of tubes or lateral migration, which is difficult to correct. Also, the lack of optometrists and physicians to perform ophthalmic surgeries in underdeveloped countries further hinders market growth.

Market Segmentation: Bicanalicular lacrimal duct stent tube segment accounted for the highest share in global lacrimal duct stent tube market.

Bicanalicular lacrimal intubation has gained popularity in treating children with nasolacrimal duct obstruction, and the younger the children, the higher the success rate. Bicanalicular lacrimal tubes consist of two probes with an overriding stent. One probe is passed over the upper punctum while the other over the lower punctum. The probes are removed, and the free ends of the silicone tube are tied in the nose and are sometimes secured with a suture. The results are better with a longer duration of tube retention. This duct stent tube continues to be most-selling in the medical sector, improving patient compliance, easier usability, better clinical outcomes, and material compatibility, thus driving product demand.

Based on end-user, the lacrimal duct stent tube market is classified into hospitals, ophthalmic clinics, and ambulatory surgical centers.

The hospital segment is expected to witness the largest market share globally due to significant hospital infrastructure advancements and a rise in hospitals in emerging countries. As lacrimal stent tubes are minimally invasive with DCR procedures, their adoption in hospitals has increased considerably. A significant increase in healthcare expenditure to develop new hospitals in developed countries to provide better medical facilities offers lucrative opportunities for the market players.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American region is projected to register the highest market share during the review period due to the strong medical industry and high healthcare expenditure. Advanced and modern medical and ophthalmology facilities with substantially rising lacrimal diseases increase the demand for lacrimal duct stent tubes. Growing per capita healthcare spending and favorable government initiatives for integrated healthcare systems in the U.S. and Canada drive regional market growth. Moreover, the rising number of retinal patients is creating ample opportunities for market players. The U.S. dominated the regional market due to its better regulatory framework for surgical devices and rising awareness among the population for such procedures in lacrimal duct obstruction and related health conditions. The industry players possess well-established direct channel collaboration with hospitals and ophthalmology clinics to cater to their patients effectively. Besides, the companies have strategized acquisitions with well-known clinics and hospitals to expand their business operation in North America.

Competitive Landscape:

The lacrimal duct stent tube market is moderately competitive, with the presence of regional and global players. Some global market players include FCI Ophthalmics, Kaneka Medical America LLC, Gunther Weiss Scientific Glassblowing Co., Inc., Aurolab, and Beaver-Visitec International, Inc, among others. The major players are implementing various growth strategies such as acquisitions, product innovation, and expansion, contributing to the lacrimal duct stent tube market's growth globally. In February 2021, FCI Ophthalmics Announced the Availability of LacriJet for Monocanalicular Nasolacrimal Intubation. LacriJet was launched in the United States. According to FCI Ophthalmics, it is the first self-retaining monocanalicular nasolacrimal intubation preloaded on a single-use injector. It consists of a single-use injector handpiece into which a silicone tube is preloaded inside a metallic probe. It has been specifically designed to reduce operating time during intubation and removal of the device. It is indicated for epiphora, congenital nasolacrimal duct obstruction (CNLDO), and canalicular laceration. In June 2020, Kaneka Corporation completed a partnership with Rohto Pharmaceutical Co., Ltd. This partnership helped to grow the business of lacrimal duct tubes. Both companies worked together to increase the sales of the product.

COVID-19 Impact: Negative impact on the global lacrimal duct stent tube market.

The nasal tissues have demonstrated the shedding of the SARS-CoV-2 virus, and nasal interventions are potential aerosol generators. It increases the risk of viral exposure from aerosols or droplets for lacrimal surgeons and optometrists. This risk can be further compounded by the face-to-face position with the patients during surgery or examination, possible coughing, and sneezing caused by the surgical procedures, thus risking medical practitioners' lives. The cancellation of non-urgent and elective lacrimal surgical procedures affects the lacrimal duct stent market.

The global lacrimal duct stent tube market report would provide an access to approximately 50 market data tables, 40 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by End User
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product Segment
    • 7.1.2. Market attractiveness index, By Product Segment
  • 7.2. Monocanalicular Lacrimal Duct Stent Tube *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Bicanalicular Lacrimal Duct Stent Tube

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By End User Segment
    • 8.1.2. Market attractiveness index, By End User Segment
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Ophthalmic Clinics
  • 8.4. Ambulatory Surgical Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. FCI Ophthalmics*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Kaneka Pharma America LLC
  • 11.3. Gunther Weiss Scientific Glass
  • 11.4. Bess Medizintechnik Gmbh
  • 11.5. Aurolab
  • 11.6. Agfa Healthcare
  • 11.7. Beaver-Visitec International, Inc
  • 11.8. Carefu(shandong) International Trade Co.,ltd
  • 11.9. Hangzhou Formed Medical Device Co., Ltd.
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us